British Journal of Clinical Pharmacology

D. Grahame-Smith (Chairman)
Annmarie Hedges (Press Editor)

Executive Editorial Board
D. J. Back R. E. Ferner M. S. Lennard G. T. Waller
T. K. Daneshmund S. H. D. Jackson G. T. McInnes P. C. Rubin

Editorial Board
N. Baber G. Edwards P. A. Meredith P. C. Rubin
D. B. Barnett M. Eichelbaum G. D. Murray M. A. Simmonds
E. Begg H. Elliott W. Nimmo A. D. Struthers
F. Bochner M. Feely B. K. Park K. L. Woods
M. J. Brodie J. D. Harry J. Posner
A. Cohen P. R. Jackson T. Pullar
J. G. Collier B. Lipworth J. M. Ritter

British Journal of Clinical Pharmacology is published monthly by Blackwell Scientific Publications Ltd for the British Pharmacological Society. Papers on all aspects of drug action in man will be considered for publication. Manuscripts (four copies) and editorial correspondence should be addressed to The Editorial Secretary, British Journal of Clinical Pharmacology, 25 John Street, London WC1N 2BL (telephone no. 071 404 4101, fax 071 831 6745). Papers are assumed to have been submitted exclusively to the journal as they become copyright on acceptance for publication. Submissions should be accompanied by a letter from the corresponding author stating that all co-authors have seen the paper and, satisfied with the content, have approved its submission to the Journal. For detailed information see ‘Instructions to Authors’ at the front of each issue.

Subscription information. British Journal of Clinical Pharmacology is published monthly (2 volumes per annum) and the subscription rates for 1994 are £299.00 (Europe), £329.00 (Rest of World), $490.00 (US and Canada), in all cases post free. Subscribers in Canada must add 7% to the value of their order to allow for Canadian GST. Subscribers in Europe must quote their VAT registration number, or state that they are not registered. Subscribers in the Netherlands who are not VAT registered must add 6% to the subscription price to allow for VAT. Orders for current subscriptions and back issues should be sent to Blackwell Scientific Publications Ltd, P.O. Box 87, Oxford OX2 0NE; all other business correspondence, including orders for offprints and advertising space, should be addressed to Blackwell Scientific Publications Ltd, Osney Meadow, Oxford OX2 0EL (telephone no. 0865 206206, telex 83535 Medbok G, fax 0865 721205).

*Post Master, send address changes to British Journal of Clinical Pharmacology, c/o Mercury Airfreight International Ltd, 2322 EF Randolph Avenue, Avenel, NJ 07001 (US Mailing Agent). Second class post paid at RAHWAY NJ.

The publisher’s policy is to use acid-free permanent paper, to the draft standard ISO/DIS 9706, made from sustainable forests using chlorine-free pulp. The paper used in this journal has an ECO-CHECK 4 star rating.

Whilst every effort is made by the publishers and editorial committee to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they and the British Pharmacological Society wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the British Pharmacological Society, the publishers and the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.
Instructions to authors

Papers will be considered for publication if they are relevant to any aspect of drug action in man, including chemotherapy. A recent issue of the Journal is a good guide to style. Further information on style can be found in Instructions to authors (Br. J. clin. Pharmac., 1982, 14, 3–6) and Symbols in Pharmacokinetics (Br. J. clin. Pharmac., 1982, 14, 7–13).

Manuscripts (four copies) should be sent to The Editorial Secretary, British Journal of Clinical Pharmacology, 25 John Street, London WC1N 2BL.

Manuscripts should be typed in double spacing on one side of standard paper (A4—210 × 297 mm). A separate title page should give the names of the authors; and the name and address of one author for correspondence. Keywords should also be supplied and a short title of not more than 50 letters should also be suggested.

Manuscripts on disk Supplying a word processor disk with the copies of your accepted manuscript will speed the publication process. Further details can be supplied on request.

Main papers should be divided into the following sections: title page, numbered summary, introduction, methods, results, discussion, acknowledgements, references, legends to figures, tables and figures.

Short reports should be set out in the same format as main papers with one exception, namely that the summary should not be numbered. The length of a short report including title, summary, and references should not exceed 1,200 words plus two figures or tables, or one of each.

General articles will be considered for publication under various headings, such as Review, Methods, Topic in Therapeutics, Personal View, or Meeting Report. Authors who plan to submit such an article should contact the Editorial Secretaries in advance for advice on the suitability of the article proposed.

Letters to the Editors Comment on previously published papers, items of topical interest, and brief original communications will be considered under this heading. The length, including references, should not exceed 800 words plus one figure or table. The letter should not be divided into sections, and the names and addresses of authors should appear at the end.

Statement Papers will be accepted only if accompanied by a statement that they have not been, and will not be, published in whole or in part in any other journal. Authors who have any doubt about possible overlap between a manuscript submitted and a published paper should draw this to the attention of the Editorial Secretaries in a letter and enclose a copy of the relevant published paper(s).

Ethical considerations The ethical aspects of all studies involving human subjects will be noted particularly when assessing manuscripts. The methods section should include a statement that the subjects consented to the study after full explanation of what was involved and should indicate whether or not the consent was obtained in writing. Details should be given of the approval of the study protocol by an ethics committee or similar body. The ethics committee which approved the protocol should be described in sufficient detail to allow the committee to be identified.

Title and Summary The title should give an informative and accurate indication of the content of the paper. The numbered summary should describe the content of the paper accurately, and the important conclusions, couched in terms which will be understood by the majority of the readers of the Journal.

Stereo-Isomers Where a drug can exist as stereo-isomers or diastereo-isomers (e.g. geo-metrical isomers), the form of compound studied must be designated as follows in the methods section. In the case of racemates a prefix rac-should precede the drug name (e.g. rac-propranolol). Where possible the absolute configuration of enantiomers should be indicated (e.g. (S)-warfarin). Similarly, geometrical isomerism should be indicated by prefixes Z/E or cis/trans. Where appropriate the interpretation of data obtained using mixtures of isomers should take account of stereochemical aspects.

Drug names As far as is possible code names for drugs, e.g. those used by pharmaceutical companies, should be avoided. Where code names have to be used the chemical name or structure of the drug should be detailed in the introduction. Where a code name has been used and a proper name (e.g. BANN, INN) becomes available before publication, authors are asked to inform the Journal of the drug name.

Units These are normally expressed as SI units. If other units are used a conversion factor should be included in the Methods section. See Editorials, Br. J. clin. Pharmac. (1983), 16, 1–7–.

Statistical methods should be described clearly in the methods section with references when appropriate. Editors and referees will be concerned particularly that any study described had sufficient statistical power for its purpose, and where appropriate considerations of the power of the study should be laid out in the methods section. In the results section 95% confidence intervals should be cited whenever possible for all important endpoints for the study.

Figures These should not be larger than A4 and may be in the form of original drawings, recorded tracings or high quality photographic prints made from them. Symbols which are to appear in figures or legends should be chosen from the following:

- ○ - ● - □ - △ - ▲ - ▼

Photographs and photomicrographs should be unmounted glossy bromide prints of good contrast, well matched and preferably with a transparent overlay for protection. The overlay should be used to indicate masking instructions, lettering or arrows. Authors are advised that figures may be redrawn by the Journal, and figures should therefore be checked particularly carefully at proof stage.

Tables These should not have more than 85 characters to a line (counting spaces between columns as 4 characters) and certainly not more than 110 characters to a line, unless absolutely unavoidable. Figure legends and tables should be typed on separate sheets of paper.

References References should be cited using the Vancouver style (see examples below). References in the manuscript text should appear as numbers in square brackets, following the authors’ names in the text if necessary. The reference list should show the references in numerical and not alphabetical order, and should include the names of all the authors (if there are more than six authors only the first three should be given followed by et al), the full title of the article, title of publication (abbreviated in accordance with the fourth edition of the World List of Scientific Periodicals), the year, volume number and first and last page numbers. References to books should, in addition, include the names of the editor, the edition number, where appropriate, and the town of origin and name of publisher. The accuracy of the references is the responsibility of the author.


Acknowledgements All support, financial or otherwise, for any work described should be acknowledged, with the exception of support from employing institutions identifiable from the title page.

Two page proofs will be supplied, one of which may be retained by the authors. The other should be corrected immediately and returned to the Press Editor. Corrections should be kept to a minimum. Extensive changes may be charged to the author.